Fennec Pharmaceuticals ex-director sells 10,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov sold 10,000 common shares on 2026-08-03 at $9.5800 per share in a sale classified as an open-market or private transaction. The sale was executed under a Rule 10b5-1 plan dated September 19, 2025, and left him holding 131,633 common shares directly.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common shares F1 | 10,000 | $9.58 | $96K |
Footnotes (1)
- F1. Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
open market or private transaction financial
non-derivative financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did FENC report for Rosty Raykov?
Was the August 3, 2026 FENC insider sale made under a Rule 10b5-1 plan?
What type of security did the FENC insider sell in this Form 4?
Is Rosty Raykov currently a director of Fennec Pharmaceuticals (FENC)?
AI-generated analysis. How Rhea-AI works. Not financial advice.